B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; AESKU.KIPP Institute, Mikroforum Ring 2, Wendelsheim 55234, Germany.
AESKU.KIPP Institute, Mikroforum Ring 2, Wendelsheim 55234, Germany.
Gastroenterol Clin North Am. 2019 Jun;48(2):307-317. doi: 10.1016/j.gtc.2019.02.009. Epub 2019 Apr 1.
Most patients affected by celiac disease (CD) are asymptomatic or hyposymptomatic and undiagnosed, and are at risk of preventable complications. Therefore, early diagnosis is highly recommended. Multiple diagnostic antibodies are available; the most frequently used is IgA to tissue transglutaminase (IgA-tTg). It may yield false results and, alone, does not address IgA deficiency. Recently, a new generation of anti-neo-epitope tTg check (IgG + IgA) has become available. It is highly sensitive and specific, covers IgA-deficient patients with CD, reflects intestinal damage, and has predictive potential in the diagnosis of CD.
大多数患有乳糜泻 (CD) 的患者无症状或症状不明显且未被诊断,存在可预防并发症的风险。因此,强烈建议早期诊断。有多种诊断抗体可供选择;最常用的是针对组织转谷氨酰胺酶的 IgA(IgA-tTg)。它可能会产生假结果,而且单独使用并不能解决 IgA 缺乏的问题。最近,新一代的抗新表位 tTg 检测(IgG+IgA)已经问世。它具有高度的敏感性和特异性,涵盖了 CD 患者的 IgA 缺乏,反映了肠道损伤,并具有在 CD 诊断中的预测潜力。